logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Hyperlipidemia

    Medications for Hyperlipidemia

    FiltersReset Filters
    26 results

    • antara

      (FENOFIBRATE)
      Lupin Pharmaceuticals, Inc.
      Usage: Antara is indicated as adjunctive therapy to diet for reducing triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL) and lowering LDL cholesterol in adults with primary hyperlipidemia when standard therapies are not possible. Its effect on pancreatitis risk and coronary heart disease outcomes is not established.

    • atorvastatin calcium

      (Atorvastatin calcium)
      NIVAGEN PHARMACEUTICALS, INC.
      Usage: Atorvastatin calcium is indicated to reduce the risk of myocardial infarction, stroke, and angina in at-risk adults. It also lowers LDL cholesterol in adults with hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and treats primary dysbetalipoproteinemia and hypertriglyceridemia as an adjunct to diet.

    • colesevelam hydrochloride

      (COLESEVELAM HYDROCHLORIDE)
      Amneal Pharmaceuticals of New York LLC
      Usage: Colesevelam hydrochloride tablets are indicated to reduce elevated LDL cholesterol in adults with primary hyperlipidemia and in boys/girls (10-17 years) with heterozygous familial hypercholesterolemia. Additionally, it is used to improve glycemic control in adults with type 2 diabetes mellitus, alongside diet and exercise.

    • colesevelam hydrochloride

      (colesevelam hydrochloride)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Colesevelam hydrochloride tablets are indicated to reduce elevated LDL cholesterol in adults with primary hyperlipidemia and in boys/postmenarchal girls aged 10-17 with heterozygous familial hypercholesterolemia. Additionally, they improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.

    • colesevelam hydrochloride

      (Colesevelam Hydrochloride)
      Glenmark Pharmaceuticals Inc.,USA
      Usage: Colesevelam hydrochloride is indicated as an adjunct to diet and exercise for reducing LDL cholesterol in adults with primary hyperlipidemia and in boys/girls aged 10-17 with heterozygous familial hypercholesterolemia. It also improves glycemic control in adults with type 2 diabetes mellitus. Not for type 1 diabetes or diabetic ketoacidosis.

    • crestor

      (Rosuvastatin)
      AstraZeneca Pharmaceuticals LP
      Usage: CRESTOR is indicated for reducing the risk of major cardiovascular events in adults at increased risk, as an adjunct to diet for lowering LDL cholesterol in various hyperlipidemias, and for treating primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It is also used in pediatric patients with familial hypercholesterolemia.

    • ezetimibe and simvastatin

      (Ezetimibe and Simvastatin)
      AvKARE
      Usage: Ezetimibe and simvastatin tablets are indicated as adjunct therapy to diet for reducing cholesterol and triglyceride levels in patients with primary or mixed hyperlipidemia, including homozygous familial hypercholesterolemia. They are part of a comprehensive approach to reduce the risk of atherosclerotic vascular disease.

    • fluvastatin sodium

      (Fluvastatin Sodium)
      Lannett Company, Inc.
      Usage: Fluvastatin sodium extended-release tablets are indicated for reducing the risk of coronary revascularization and slowing coronary atherosclerosis in adults with coronary heart disease. They also help lower LDL cholesterol in adults with primary hyperlipidemia and in pediatric patients aged 10 and older with heterozygous familial hypercholesterolemia.

    • nexletol

      (Bempedoic Acid)
      Esperion Therapeutics, Inc.
      Usage: NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.

    • nexlizet

      (Bempedoic Acid and Ezetimibe)
      Esperion Therapeutics, Inc.
      Usage: NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated as an adjunct to diet for reducing LDL-C in adults with primary hyperlipidemia, including HeFH. Bempedoic acid also lowers myocardial infarction and coronary revascularization risk in adults unable to take statins, with or without established cardiovascular disease.